Table 1.
Demographic and clinical information for the study cohort
| EGFR (+) | ALK (+) | KRAS (+) | p | |
|---|---|---|---|---|
| N = 75 | N = 21 | N = 15 | ||
| Gender | ||||
| Male | 24 (32%) | 8 (38.10%) | 5 (33.33%) | 0.83 |
| Female | 51 (68%) | 13 (61.90%) | 10 (66.67%) | |
| Age | ||||
| Mean ± SD | 57.43 ± 12.09 | 53.81 ± 14.79 | 63.67 ± 6.40 | 0.09 |
| Race | ||||
| Asian | 35 (46.67%) | 7 (33.33%) | 1 (6.67%) | |
| Caucasian | 34 (45.33%) | 13(61.90%) | 11 (73.33%) | 0.016 |
| Other* | 6 (8%) | 1 (0.04%) | 3 (20%) | |
| History of Smoking | ||||
| Yes | 20 (26.67%) | 5 (23.80%) | 12 (80%) | <0.001 |
| No | 55 (73.33%) | 16 (76.19%) | 3 (20%) | |
| Histology | ||||
| Adenocarcinoma | 71 (94.67%) | 21 (100%) | 13 (86.67%) | 0.50 |
| Other** | 4 (5.33%) | 0 (0%) | 2 (13.33%) | |
| Other Metastatic Sites | ||||
| Bones | 45 (60%) | 9 (34.62%) | 4 (26.67%) | |
| Lymph Nodes | 27 (36%) | 4 (15.38%) | 3 (20%) | |
| Lung | 26 (34.67%) | 4 (15.38%) | 1 (6.67%) | 0.99 |
| Liver | 22 (29.33%) | 5 (19.23%) | 2 (13.33%) | |
| Pleura | 13 (17.33%) | 2 (7.69%) | 1 (6.67%) | |
| Other*** | 9 (12%) | 0 (0%) | 0 (0%) | |
*
American Indian or Alaska Native, African American, Native Hawaiian, or Pacific Islander
**
Squamous cell lung carcinoma, adenosquamous cell lung cancer, lung carcinosarcoma, non-small cell lung carcinoma (NOS)
***
Kidneys, mediastinum, pancreas, pericardium